Abstract
Introduction: Cancer is the uncontrolled growth and development of cells in the body, and is one of the foremost reasons of deaths throughout the world. Immunotherapy is a broad category of cancer therapies that triggers the body's immune system to fight cancer cells. Nivolumab, a monoclonal antibody, is used an immunotherapy drug that binds to the Programmed Cell Death protein (PD-1) to help immune cells kill cancer cells better and is used to treat many different types of cancer. This study is about two cancer patients, one being a case of Squamous Cell Carcinoma of the Right Lung, another being a case of metastatic Stage IV Renal Cell Carcinoma. They were treated with low-dose Nivolumab and resulted in remission of the malignancy without any significant complications. Case Presentation: The current study was conducted with 2 Bangladeshi male patients. The first patient, case of Carcinoma Lung, 55 years old, and the second patient, Renal Cell Carcinoma, 57 years old. They were treated with 6 cycles of Nivolumab at 40 mg dose for immunotherapy regimen. Both of them are clinically stable and no complications have been detected. Conclusion: Treatment with Nivolumab in such fatal cancers has demonstrated remarkable clinical response with significant remission of the disease. In addition, adverse effects are minimal compared to previous drug regimens.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
